{"id":"NCT00548340","sponsor":"Vanda Pharmaceuticals","briefTitle":"VEC-162 Study in Adult Patients With Primary Insomnia","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20 mg/Day and 50 mg/Day) in the Treatment of Primary Insomnia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2008-02","completion":"2008-06","firstPosted":"2007-10-23","resultsPosted":"2014-10-15","lastUpdate":"2014-10-15"},"enrollment":322,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Insomnia"],"interventions":[{"type":"DRUG","name":"VEC-162 20 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"VEC-162 50 mg","otherNames":[]}],"arms":[{"label":"VEC-162 20 mg","type":"EXPERIMENTAL"},{"label":"VEC-162 50 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.","primaryOutcome":{"measure":"Average Change From Baseline - Latency to Persistent Sleep (LPS)","timeFrame":"Baseline, Night 1, and Night 8 measurement","effectByArm":[{"arm":"VEC-162 20 mg","deltaMin":45,"sd":2.965},{"arm":"VEC-162 50 mg","deltaMin":46.4,"sd":2.954},{"arm":"Placebo","deltaMin":28.3,"sd":3.02}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":109},"commonTop":["Headache","Nasopharyngitis","Blood Creatine Phosphokinase Increased","Urinary Tract Infection"]}}